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| INTRODUC TI ON
Marfan syndrome (MFS) is mainly caused by the fibrillin-1 (FBN1) gene mutation and is a hereditary disorder of connective tissue with effects on multiple systems including cardiovascular, skeletal and ocular.
1 FBN1 encodes the extracellular matrix protein FBN1 and is involved in the formation of complex extracellular structures in the arteries. FBN1 mutation can lead to contractile dysfunction of smooth muscle cells (SMCs) with consequent reduced tensile strength of aortic tissue. 2 Aortic complications such as aortic dilatation and dissection are the main cause of morbidity and mortality in patients with MFS. 3 Although considerable progress has been made over the past decades in the treatment of MFS-induced cardiovascular injury, including medical and surgical interventions, efficacy has been limited due to the unclear molecular aetiologies. An understanding of the fundamental molecular mechanisms that underlie MFS will provide a novel strategy for MFS management.
The wall of the aorta is composed of three layers: intima, media and adventitia. Recent research has revealed a range of vascular progenitor cells (VPCs) in the adventitia of the vessel wall that are positive for stem cell antigen-1(Sca-1) or c-kit. [4] [5] [6] These VPCs can give rise to many cell lineages, including endothelial cells and SMCs. 7, 8 It has been well documented that VPCs contribute to cardiovascular regeneration therapies. 5 Transplantation of VPCs isolated from the adventitia of patients with coronary artery bypass graft has been shown to greatly enhance blood perfusion recovery and neovascularization in a mouse model of hindlimb ischaemia, 9 demonstrating their great potential in vascular disease treatment.
Nevertheless, the function of stem cells usually declines in a disease milieu. 10 It remains unclear whether the function of VPCs declines in patients with MFS.
A FBN1 defect activates transforming growth factor beta (TGF-β) signalling, leading to vascular injury. [11] [12] [13] Accumulating evidence has shown that TGF-β is involved in regulation of stem cell senescence. Treatment with TGF-β can induce cellular senescence of young MSCs but treatment with anti-TGF-β antibodies can reduce cellular senescence of old MSCs. 14 Inhibition of TGF-β1 signalling significantly inhibits serum-free-induced endothelial cell senescence and thereby improves endothelial function. 15 Disrupted mitochondrial dynamics that are regulated by fusion and fission are strongly associated with cellular senescence. 16, 17 Mitochondrial fission is mainly regulated by dynamin-related protein 1 (Drp1) and mitochondrial fission factor (Mff) whereas mitochondrial fusion is mediated by mitofusion (Mfn) 1, Mfn2 and optic atrophy 1 (Opa1) proteins. Whether TGF-β1 induces VPC senescence via regulation of mitochondrial dynamics and the underlying mechanisms have not been determined. In this study, we revealed that VPCs isolated from MFS exhibited cellular senescence. Importantly, we found that TGF-β1 disrupted mitochondrial dynamics via regulation of the adenosine monophosphate-activated protein kinase (AMPK) signalling pathway, leading to VPC senescence in MFS patients.
| MATERIAL S AND ME THODS

| C-kit VPC isolation, culture and characterization
Vascular progenitor cells were isolated from control donors and patients with MFS at Guangdong Provincial People's Hospital, China.
Written informed consent was obtained from all study patients and detailed information is summarized in Table 1 . This study was approved by the research ethics board of Guangdong Provincial
People's Hospital.
Human VPCs were isolated, sorted and cultured as previously described. 18 Briefly, aorta specimens were taken from the ascending aorta of control donors and MFS patients. After removing the adipose tissue, the adventitial tissue was separated from the media and intima. The adventitia was cut into 1-2 mm 3 pieces and digested in Liberase TL (Roche, 5401020001) at 37°C for 3.5 hours, then passed through a 100 μm and 70 μm cell strainer to obtain cell suspension. VPCs were sorted using anti-C-kit immunomagnetic microbeads (Miltenyi Biotec, 130-091-332) and a magnetic cell separator (Miltenyi Biotec, 130-042-201), then cultured in DMEM/F12
containing 15% FBS, streptomycin and penicillin 100 U/mL and leukaemia inhibitory factor (LIF) 10 ng/ml. The VPCs with passage 3-4
were used in the current study. Both control-VPCs and MFS-VPCs were passaged at 3-day intervals and the same cell number (100 000 cells per 6-cm dish) was plated. Population doubling was measured at each passage. were used.
The differentiation capacity of VPCs into SMCs, osteocytes and adipocytes was evaluated as previously described. 19, 20 TA B L E 1 Demographic characteristics of the study patients 
| Scratch-wound assay
Control-VPCs and MFS-VPCs were seeded in a 12-well plate and cultured with complete culture media. When cells reached 90% confluence, scratches of the same width were made on the bottom of the plate using a 1 mL pipette tip. Cells were carefully washed with PBS to remove cell debris and then incubated with serum-free medium in an incubator with 5% CO 2 at 37°C. After 24 hours incubation, the migration of VPCs into the 'wound' area was evaluated by a phase contrast microscope.
| Transwell assay
The migration capacity of VPCs from different groups was assessed by transwell inserts with 8.0 μm micron pore membrane filters in a DEGs to the number of total sequenced genes involved in the corresponding pathway. We selected significant DEGs that were enriched in the cellular senescence pathway to plot the heatmap. Unknown genes and genes with missing expression in more than two samples were discarded.
| Western blotting
| MitoTracker staining
The mitochondrial morphology of VPCs was examined by
MitoTracker Green FM (Invitrogen, M7514). Briefly, VPCs from different groups were incubated in the dark for 30 minutes with DMEM supplemented with 20 nmol/L MitoTracker Green FM. After washing with PBS three times, cells were mounted with 4′, 6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Inc.) and photographed using a confocal microscope.
| Immunofluorescence staining
Immunofluorescence staining was carried out according to the protocol as previously described. 23 Briefly, control-VPCs and MFS-VPCs 
| Small-interfering RNA (siRNA) silencing
TGF-β1-siRNA (sc-44146), Mfn2-siRNA(sc-43928) and control siRNA(sc-37007) were used to transfect VPCs using a Lipofectamine
RNAiMAX Reagent Kit (Invitrogen, 13778030) according to the protocol. Seventy-two hours after transfection, VPCs were collected and the silencing efficiency was examined by Western blotting.
| Statistical analysis
All groups by one-way ANOVA followed by the Bonferroni test. A Pvalue <0.05 was considered statistically significant.
| RE SULTS
| Characterization of VPCs
Previous studies have shown the existence of VPCs that express Sca-1, CD34 and C-kit in the adventitia of the vessel wall. 24, 25 We 
| VPCs isolated from patients with MFS exhibit cellular senescence
Cellular senescence is closely associated with reduced cell function including reduced differentiation capacity and decreased proliferation. 26 Therefore, we first conducted immunofluorescent assay to identify senescent VPCs in the ascending aorta of control donors and MFS patients. As shown in Figure 2A 
| Transcriptomic comparison of controlVPCs and MFS-VPCs
To further verify the senescence of MFS-VPCs, we performed genome-wide RNA sequencing (RNA-seq). A total of 1724 up-regulated genes and 2555 down-regulated genes were obtained in MFS-VPCs relative to control-VPCs ( Figure 3A ). Gene ontology term enrichment analysis showed that cellular process contains the highest number of significant differentially expressed genes (both up-and downregulated genes) ( Figure 3B ). Then, we checked the enrichment analysis on the cellular process-related pathways and found that cell cycle, cellular senescence and signalling pathways regulating the pluripotency of stem cells were significantly enriched ( Figure 3C ).
We further examined these pathways and established that 81 differentially expressed genes between control-VPCs and MF-VPCs belong to the cellular senescence pathway, one of the top-ranked cellular process-related pathways (P-value = 3.84e-5), accounting for more than 25% of the total detected cellular senescence-related genes. After removing novel DEGs, the samples could be correctly clustered according to the remaining known genes enriched in the cellular senescence pathway ( Figure 3D ). These data suggested a critical role of cellular senescence in the MFS-VPCs. and SA-β-gal activity in MFS-VPCs ( Figure S4B ,C). These data suggest that TGF-β1 regulates the cellular senescence of VPCs.
| TGF-β1 regulates cellular senescence of VPCs in MFS
| TGF-β1 regulates VPC senescence via mitochondrial ROS generation
Accumulating evidence shows that elevation of reactive oxidative stress (ROS) generation contributes to cellular senescence. 27, 28 We 
| TGF-β1 induces mitochondrial fusion in VPCs
It has been reported that abnormal mitochondrial dynamics are closely associated with mitochondrial ROS generation. 29 We examined the mitochondrial morphology in control-VPCs and MFS-VPCs using MitoTracker staining. Surprisingly, compared with control-VPCs, Figure 6A ,B).
MFS-VPCs exhibited increased mitochondrial length (
To our knowledge, Drp1 leads to mitochondrial fission whereas Mfn2 is correlated with mitochondrial fusion. Therefore, we measured the expression level of p-Drp1 and Mfn2 in control-VPCs and MFS-VPCs.
Western blotting showed that compared with control-VPCs, Mfn2
was greatly enhanced whereas p-Drp1 was markedly reduced in MFS-VPCs ( Figure 6C ), indicating mitochondrial fusion in MFS-VPCs. 
| AMPK signalling is involved in TGF-β1 mediation of mitochondrial dynamics
The AMPK signalling pathway plays a critical role in regulation of mitochondrial dynamics. 30 We therefore examined AMPK activation in control-VPCs and MFS-VPCs. We found that p-AMPK was markedly VPCs can migrate into the media or the intima to differentiate into SMCs or endothelial cells, participating in repair of the vessel to restore function. 18, 33 In this study, we also found a population of VPCs expressing c-kit in the adventitia of the aortic root. We revealed that as well as c-kit, these cells expressed similar surface markers to mesenchymal stem cells such as CD90 and CD105. Importantly, these
| D ISCUSS I ON
VPCs also can differentiate into adipocytes and osteocytes.
Cardiovascular complications are the major clinical feature of MFS. MFS patients usually suffer from aortic aneurysms that can Data are expressed as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar = 100 μm fibroblast senescence; meanwhile excessive ROS can in turn further activate TGF-β1, forming a positive TGF-β1-ROS autocrine loop. 37 In this study, we showed that administration of TGF-β1 could induce VPC cellular senescence via ROS generation and treatment of MitoTempo attenuated this process, suggesting that TGF-β1-induced ROS accumulation is responsible for VPC senescence. Nevertheless, the relationship between TGF-β1 and ROS generation has not been fully elucidated.
It is well known that mitochondria are the major source of ROS production. There is increasing recognition that altered mitochondrial dynamics are responsible for ROS overproduction. Depletion of protein disulfide isomerase A1 (PDIA1) promotes mitochondrial fission and elevates ROS generation, driving the senescence of endothelial cells. 38 In contrast, abnormally elongated mitochondria induce ROS production, thereby triggering mammalian senescence. 39 Furthermore, depletion of OPA1 leads to mitochondrial fission and rescues cells from Data are expressed as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar = 100 μm senescence-associated phenotypic changes. 39 Senescent human adipose-derived mesenchymal stem cells exhibit increased mitochondrial elongation and ROS generation, suggesting that mitochondrial fusion contributes to cellular senescence. 40 Thus, mitochondrial fusion or fission can initiate cellular senescence and may be cell type-and contextspecific. However, the connection between mitochondrial fusion and ROS remains unclear. Increased ROS may lead to further mitochondrial fusion, causing further elevation in ROS generation, thus forming a vicious loop. In this study, we showed that compared with control-VPCs, the mitochondria in MFS-VPCs were greatly elongated. TGF-β1 treatment increased Mfn2 expression and decreased p-Drp1 in control-VPCs.
Nevertheless, Mfn2-siRNA administration inhibited TGF-β1-induced mitochondrial fusion and ROS generation, and thus attenuated the cellular senescence of control-VPCs. These results support the notion that TGF-β1 induces VPC senescence via regulation of mitochondrial fusion.
The next question is how TGF-β1 regulates mitochondrial fusion in
VPCs. Previous studies have demonstrated that AMPK signalling mediates mitochondrial dynamics. 41, 42 AMPK activation can phosphorylate MFF, a critical receptor protein for Drp1, to induce mitochondrial fission. 30 We found that p-AMPK was significantly reduced in MFS-VPCs, combined with mitochondrial fusion in VPCs. We presumed that downregulation of p-AMPK could induce mitochondrial dysfunction. It has been reported that AMPK activation induces mitochondrial dysfunction, leading to human fibroblasts senescence. 43 In contrast, in this study, we found that treating MFS-VPCs with AICAR reversed mitochondrial fusion and attenuated cellular senescence, suggesting that AMPK activation inhibits MFS-VPCs senescence. This contradictory phenomenon may be cell type-and stimuli-dependent. It has been demonstrated that TGF-β1 activity impairs mitochondrial function in human skeletal muscle cells via suppression of AMPK activation. 44 Furthermore, the activation of AMPK can inhibit TGF-β1 release. 45 Collectively, there seems to be a positive feedforward mechanism by which TGF-β1 inhibits AMPK activation, that in turn down-regulation of AMPK activation increases TGF-β1 release. Consistent with this finding, in this study we showed that administration of TGF-β1 significantly inhibited AMPK activation, leading to mitochondrial fusion. AICAR treatment abrogated TGF-β1-induced mitochondrial fusion and senescence in control-VPCs.
There are also some limitations in this study. 
